Authors


Kevin Schwartz, MD, MSc, FRCPC

Latest:

"Antibiotic Never Events": The Ideal Target to Reduce Antimicrobial Exposure

By stopping unnecessary antibiotics before they start, clinicians can avoid unnecessary harm to the patient and the population.


Sarah M. Michienzi, PharmD

Latest:

Antiretroviral Stewardship: The Time is Now

In this narrative review of studies evaluating antiretroviral stewardship programs (ARVSPs), we propose core elements for ARVSPs that are based on published evidence, clinical experience, and adapted from antimicrobial stewardship programs.


Pharmacy Times&reg Editorial Staff

Latest:

National HIV Testing Day: Free Screening Services Available at Walgreens

Testing and information will be available at select Walgreens stores in more than 260 cities on National HIV Testing Day on Thursday between 10 am and 7 pm.



Cecilia Pessoa Gingerich

Latest:

E-cigarette Users, Especially Women, May Be More Susceptible to Flu

Early research found that e-cigarette use affects the immune system response to the flu virus and the effects are different for female and male users.


Alyssa B. Christensen, PHARMD, BCIDP

Latest:

Wiki-What? Navigating WikiGuidelines and Leveraging Their Advantages

WikiGuidelines produces novel clinical practice guidelines developed with pragmatic, applicable methodology, including a diverse author group.


Jennifer Lo, PharmD

Latest:

"Antibiotic Never Events": The Ideal Target to Reduce Antimicrobial Exposure

By stopping unnecessary antibiotics before they start, clinicians can avoid unnecessary harm to the patient and the population.


Stephanie Spivack, MD

Latest:

A Case of Varicella-Zoster Meningitis Causing Postoperative Fevers After Umbilical Hernia Repair

Due to worsening headaches and unrevealing cross-sectional imaging and ascites fluid analyses, this patient's differential evolved toward a central nervous system source.


AMY CHENG, PHARMD, AAHIVP

Latest:

Treating HCV in HIV-Coinfection: Still a Therapeutic Dilemma?

Despite the availability of highly active agents against HCV, HIV-infected patients require special considerations for drug interactions when considering treatment options.


Caitlyn Bahrenburg

Latest:

Site-Specific Labeling Provides New Insight on Influenza Virus Variation

A new method assessing the influenza A strain provides investigators with a more detailed look at influenza viruses.


Tiffany Lee, PharmD, BCIDP

Latest:

Vancomycin Loading Doses Improve Target Timing and Safety in 61,000+ Cases

At MAD-ID 2025, Tiffany Lee, PharmD, presents multi-center findings showing no increase in AKI with higher initial dosing.


Gena M. Burch, PharmD, MS

Latest:

Individualized Beta-Lactam Therapy and Monitoring

Elevated beta-lactam concentrations have been associated with neurotoxic adverse effects, including seizures and mental status changes.


Bryan T. Alexander, PharmD, BCIDP, AAHIVP

Latest:

A Chance to Improve Hepatitis C Care for PWID

Here is a review of an opportunistic treatment approach to HCV infection in this patient population in a European study and some of the potential challenges in applying it in the United States.


Whitney J. Palmer

Latest:

Those With HIV Shown to Have More Coronary Plaque

Even if HIV-positive individuals have a low-to-moderate risk for cardiovascular disease, they still experience more coronary plaque.



Syra Madad, DHSC, MSC; and Vikram Mukherjee, MD

Latest:

10 Key Pillars to an Effective Ebola Response

EVD outbreaks this year serve as a reminder of the virus’ severity and the importance of having a containment strategy in place.


Jordan M. Chiasson, PharmD, BCIDP

Latest:

Intravenous Antimicrobials: Is It Time to Push?

Intravenous (IV) push is an attractive option to administer antimicrobial therapy to patients in an efficient and effective manner in a variety of clinical settings. While many advantages to IV push administration exist, clinicians should be mindful of available literature regarding safety profiles, pharmacokinetic/pharmacodynamic characteristics, and clinical data for IV push antimicrobial administration prior to utilizing it in specific patient populations.


Kristin L. Feick, PHARMD, BCPS

Latest:

Oral Therapeutic Options to Prevent Disease Progression From COVID-19 in an Ambulatory Setting

As the number of COVID-19 cases continues to rise, oral treatment options for at-home use are in demand to provide early intervention and reduce the progression to severe disease, hospitalization, and death.


Alba Azola, MD

Latest:

Navigating Long COVID and ME/CFS Overlap

Alba Azola, MD discusses the challenges of diagnosing and managing Long COVID and its overlap with ME/CFS, emphasizing the need for individualized care and ongoing research.


Michael Trisler, PharmD, MPH, BCIDP

Latest:

Daptomycin as Frontline Therapy for MRSA Bacteremia: Has the Time Come?

Findings increasingly suggest the mortality risk may be reduced by initiating daptomycin within 3 days of infection.


Jiye Park, PharmD

Latest:

Oral Vancomycin "Tail" Offers No Added Benefit for CDI Prophylaxis

At MAD-ID 2025, Jiye Park, PharmD, presents findings showing once-daily dosing is effective, with no added benefit from extended vancomycin use after antibiotics.


Juanita Mora, MD

Latest:

Protecting Older Adults From Severe COVID-19

Allergist and immunologist Juanita Mora, MD, urges vaccination, masking, and outreach to safeguard vulnerable communities.


Catherine Bertrand Ferrandis, DVM

Latest:

Combating Misinformation on Antimicrobials

Insights from Catherine Bertrand Ferrandis, DVM, on the role of One Health and interdisciplinary collaboration.


Onyema Ogbuagu, MBBCH, FACP, FIDSA

Latest:

Phase II Study Shows Efficacy of 6-Month Regimen of Lenacapavir, Teropavimab, and Zinlirvimab for HIV

Onyema Ogbuagu, MBBCh, FACP, FIDSA discussed 96% virologic suppression with lenacapavir-based therapy, showing similar results to daily oral regimens.


Gregory Fox, PhD, MIPH, FRACP, MBBS, BSc(Med), GAICD

Latest:

Challenges and Implications of the V Quinn TB Prevention Trial

Gregory Fox, PhD outlines the trial's challenges, the impact of combining results with the TB Champ trial, and the role of collaboration in strengthening research outcomes.


Lynn Wardlow, PharmD, MBA, MS, BCIDP, AAHIVP

Latest:

Treating Persistent Methicillin-susceptible Staphylococcus aureus (MSSA) Bacteremia

Emerging treatment options for patients with persistently positive blood cultures with Methicillin-Susceptible Staphylococcus aureus (MSSA).


Robert H. Hopkins Jr. MD

Latest:

How Should Individuals Interpret the FDA’s Latest COVID-19 Vaccine Authorization?

Robert Hopkins, Jr, MD, medical director of the National Foundation for Infectious Diseases (NFID), discusses what patients are asking about with regards to the vaccines and what the general public should continue to know about their medical value.


Cynthia Miller, MD, MPH

Latest:

The Tripledemic as a Precursor to Stakeholder Alignment under the Quintuple Aim

Infectious disease outbreaks will continue to increase and trying to find strategies to ensure providers are cared for to prevent burnout and shortage staffing is essential if another pandemic arises.



William Cappuccio, PharmD

Latest:

A Plea for New Guidance and Research: Low-Level Viremia in Persons Living With HIV

Current guidelines and primary literature for managing persons living with HIV who have persistently low levels of HIV RNA are scarce. Considering the risks associated with this phenomenon, a call for further guidance and more robust studies are needed for these patients.

© 2025 MJH Life Sciences

All rights reserved.